Pfizer Vows Disciplined Financial Allocation; Will Not Chase Price For Buyouts In Markets Like India
This article was originally published in PharmAsia News
WASHINGTON - As the socioeconomic shift gains pace and healthcare is given a higher priority by governments, emerging markets like China, Brazil and India have received heightened attention from global companies looking for deal-making opportunities, but lately, unexpected hurdles have cropped up in the way. "Overly exuberant expectations" may be making future alignments hard, say high level seasoned M&A experts
You may also be interested in...
Pfizer India Managing Director Kewal Handa On Drug Pricing, Patents And Access: An Interview With PharmAsia News (Part 2 of 2)
In one of his final interviews before retirement, Pfizer Managing Director Kewal Handa discusses the Indian government’s policies on drug pricing, compulsory licensing and patents, and foreign direct investments.
Emerging markets continued to play a large role in company presentations during the industry’s largest investor conference. In this feature, PharmAsia News takes a closer look.
Pfizer's Salomon Azoulay And Bing Yan On Prevenar, Partnering In China Post-Lipitor: An Interview With PharmAsia News (Part 2 of 2)
Pfizer Inc. CEO Ian Read recently affirmed Pfizer's commitment to emerging markets, choosing to keep its established products unit in-house even as he looks to divest non-core assets like the animal health and nutrition business units. Just one week after the announcement of Read's plan, Salomon Azoulay, Pfizer's senior VP for medical & development emerging markets, and Pfizer China Vaccines Lead Bing Yan sat down with PharmAsia News' Shanghai Bureau to talk about Pfizer's blockbuster vaccines Prevenar and Prevenar 13 - marketed in the U.S. as Prevnar - in what will be the world's largest vaccines market. Azoulay was in town to explore partnerships in China, a topic he also discusses in this interview, as well as the importance of physician education in emerging markets.